---
id: clock-bio-rejuvenation-atlas
slug: clock-bio-rejuvenation-atlas
entity_type: commercial
status: operational
data_completeness: high
last_researched: 2025-01-27
researcher: AI Assistant
version: 1.1
name: clock.bio - Rejuvenation Gene Atlas
description: "Biotechnology company developing the world's first comprehensive map of genes responsible for cellular rejuvenation. Through genome-wide CRISPR activation screens in human iPSCs, identified 100+ key genetic targets that reverse aging. Platform integrates geneAge Atlas (gene discovery), imAge (AI age measurement), and clinAge (clinical validation) for developing rejuvenation therapies."
mission: To extend human healthspan by developing regenerative therapies that reverse the hallmarks of aging. The company aims to decode the rejuvenation genome to identify genetic programs that enable cells to reverse aging, translating these insights into therapeutic interventions including skin rejuvenation topicals, nutraceuticals, and systemic therapies.
entity_data:
  focus: Rejuvenation biology company developing therapies that extend human healthspan by decoding the rejuvenation genome and validating interventions that reverse cellular aging
  status: operational
  founded: 2023
  website: "https://clock.bio/"
  industry: Biotechnology
  employees:
  as_of: 2024
  range: 10-16
  legal_name: clock.bio Ltd.
  headquarters:
  city: Cambridge
  state: Cambridgeshire
  address: The Clifford Allbutt Building, Puddicombe Way, Cambridge, CB2 0AW, United Kingdom
  country: United Kingdom
taxonomy:
  geography: United Kingdom
  ai_technology:
  - Predictive ML/DL
  primary_focus:
  - Aging Clocks
  - Cellular Rejuvenation
  aging_approach:
  - Cellular Rejuvenation
  - Diagnostics/Age Assessment
  target_biology:
  - General Aging/Longevity
  development_stage: operational
  organization_type: commercial
  organization_subtype: operational
  therapeutic_modality: []
organizations:
  -
    name: clock.bio
    role: primary
    org_type: company
    legal_name: clock.bio Ltd.
    founded: 2023
    website: "https://clock.bio/"
    status: operational
    role_description: Primary organization - developer of Rejuvenation Gene Atlas and integrated platform
    contribution_description: Developed genome-wide CRISPR activation screens in iPSCs, processed 3M cells with AI/ML analysis to identify 100+ rejuvenation genes. Built integrated platform (geneAge + imAge + clinAge). Raised $9.3M in funding.
  -
    name: Milner Therapeutics Institute, University of Cambridge
    role: institution
    org_type: research_center
    website: "https://www.cam.ac.uk/"
    status: operational
    role_description: Partner institution providing research facilities and collaboration opportunities
    contribution_description: clock.bio is based at Milner Therapeutics Institute, providing access to cutting-edge research facilities, collaboration opportunities, and proximity to world-class academic research in regenerative medicine and stem cell biology
products:
  -
    name: Skin Rejuvenation Topicals
    type: therapy
    status: Preclinical Development
    development_stage: Research / Preclinical
  -
    name: Nutraceuticals
    type: therapy
    status: Preclinical Development
    development_stage: Research / Preclinical
  -
    name: Systemic Therapies
    type: therapy
    status: Discovery
    development_stage: Research / Preclinical
  -
    name: clinAge Platform
    type: platform
    status: In Development
    development_stage: Research / Preclinical
  -
    name: imAge
    type: ai_model
    status: Operational
    development_stage: Operational
  -
    name: Rejuvenation Gene Atlas
    type: platform
    status: Research and Development
    development_stage: Research / Preclinical
links:
  -
    url: "https://diotimes.com/en/clock-bio-appoints-former-biontech-executive-dr-michael-boehler-as-chief-business-officer/"
    type: article
    title: clock.bio Appoints Former BioNTech Executive Dr. Michael Boehler as Chief Business Officer
  -
    url: "https://www.biospace.com/press-releases/clock-bio-raises-5-3m-seed-funding-and-decodes-genetic-atlas-of-human-rejuvenation-factors"
    type: press_release
    title: clock.bio Raises $5.3M Seed Funding and Decodes Genetic Atlas of Human Rejuvenation Factors
  -
    url: "https://clock.bio/news/"
    type: video
    title: "Our CEO speaks at BioAge's podcast about technology, progress and vision at clock.bio"
  -
    url: "https://clock.bio/clock-bio-raises-5-3m-for-rejuvenation-roadmap/"
    type: article
    title: clock.bio raises 5.3M for rejuvenation roadmap
  -
    url: "https://clock.bio/clock-bio-to-slow-ageing-with-5-3m-funding-for-atlas-of-rejuvenation/"
    type: article
    title: clock.bio to slow ageing with 5.3M funding for Atlas of rejuvenation
  -
    url: "https://clock.bio/clock-bio-decodes-atlas-of-rejuvenation/"
    type: article
    title: clock.bio decodes Atlas of Rejuvenation
  -
    url: "https://clock.bio/clock-bios-atlas-of-rejuvenation/"
    type: article
    title: "clock.bio's Atlas of Rejuvenation"
  -
    url: "https://www.prnewswire.com/news-releases/clockbio-appoints-former-biontech-executive-dr-michael-boehler-as-chief-business-officer-302539598.html"
    type: press_release
    title: clock.bio Appoints Former BioNTech Executive Dr. Michael Boehler as Chief Business Officer
  -
    url: "https://www.businesswire.com/news/home/20241009483345/en/clock.bio-Raises-%245.3M-Seed-Funding-and-Decodes-Genetic-Atlas-of-Human-Rejuvenation-Factors"
    type: press_release
    title: clock.bio Raises $5.3M Seed Funding and Decodes Genetic Atlas of Human Rejuvenation Factors
  -
    url: "https://www.businesswire.com/news/home/20230831929429/en/clock.bio-Launches-to-Decode-Rejuvenation-Biology-Across-the-Human-Genome"
    type: press_release
    title: clock.bio Launches to Decode Rejuvenation Biology Across the Human Genome
---

# clock.bio - Rejuvenation Gene Atlas

## Description

Biotechnology company developing the world's first comprehensive map of genes responsible for cellular rejuvenation. Through genome-wide CRISPR activation screens in human iPSCs, identified 100+ key genetic targets that reverse aging. Platform integrates geneAge Atlas (gene discovery), imAge (AI age measurement), and clinAge (clinical validation) for developing rejuvenation therapies.

## Mission

To extend human healthspan by developing regenerative therapies that reverse the hallmarks of aging. The company aims to decode the rejuvenation genome to identify genetic programs that enable cells to reverse aging, translating these insights into therapeutic interventions including skin rejuvenation topicals, nutraceuticals, and systemic therapies.

## Company Information

**Legal Name**: clock.bio Ltd.
**Founded**: 2023
**Industry**: Biotechnology
**Employees**: {"as_of":"2024","range":"10-16"}
**Focus**: Rejuvenation biology company developing therapies that extend human healthspan by decoding the rejuvenation genome and validating interventions that reverse cellular aging
**Website**: https://clock.bio/

## Scientific Background

```yaml
key_concepts:
  ipscs:
  term: iPSCs (Induced Pluripotent Stem Cells)
  why_used: Naturally possess rejuvenation ability - reset biological age markers
  definition: Adult cells reprogrammed to embryonic-like state, can become any cell type
  practical_application: Used as model system to study rejuvenation genes
  biological_age:
  term: Biological Age vs Chronological Age
  definition: Biological age reflects actual cellular health based on molecular markers
  crispr_activation:
  term: CRISPR Activation
  definition: Modified CRISPR (dCas9) that turns genes ON without cutting DNA
  distinction: Activation is reversible, unlike permanent DNA editing
  how_it_works: Guide RNA + dCas9 + activator proteins (VPR/SAM) boost gene expression
  rejuvenation_genome:
  term: Rejuvenation Genome
  definition: Complete set of genes that reverse aging when activated
  single_cell_rna_seq:
  term: Single-cell RNA-seq
  definition: Measures gene expression in individual cells separately
  why_needed: Reveals cellular diversity and rare cell states
historical_context:
  aging_research_evolution:
  crispr_era: "2010s-present: Functional testing, systematic screens, causal identification"
  genomics_era: "2000s-2010s: GWAS, transcriptomics, epigenetic clocks"
  traditional_era: "Pre-2000s: Observational studies, hypothesis-driven"
  clock_bio_contribution: Systematic activation screens for aging reversal + single-cell + AI
  crispr_activation_development:
  timeline: "2013: First dCas9, 2015: VPR/SAM systems, 2016-2020: Adoption for screens, 2020s: Large-scale screens"
  key_advances:
  - dCas9-VPR strong activation
  - SAM multiplexed activation
  - Genome-wide guide libraries
  - Lentiviral delivery systems
rejuvenation_mechanism:
  how_ipscs_age: Artificially aged via prolonged culture, stress, or DNA damage - develop aging markers
  where_aging_occurs: "Inside cells: DNA damage, telomere shortening, epigenetic changes, mitochondrial dysfunction, protein quality control decline"
  aging_hallmarks_measured:
  - DNA damage (γH2AX, 53BP1)
  - Telomere length
  - DNA methylation age
  - Mitochondrial function
  - Senescence markers (p16, p21)
  - Gene expression signatures
methodological_comparisons:
  vs_traditional:
  traditional: Observational studies (correlative), candidate gene testing (<100 genes), bulk RNA-seq (loses heterogeneity)
  clock_bio_advantages:
  - Systematic genome-wide (~20,000 genes)
  - CRISPR activation identifies causal genes
  - Single-cell resolution captures rare states
  - Tests activation (gain-of-function)
  - Uses iPSCs natural rejuvenation as readout
  vs_other_crispr_screens:
  typical: Survival/death screens, disease phenotypes, knockout screens
  clock_bio_innovation:
  - Activation screen for aging reversal
  - Genome-wide in human iPSCs
  - 3M cells single-cell resolution
  - Biological age as multi-dimensional readout
  - AI integration for pattern recognition
```

## Lessons Learned

### Achievements

- Completed first comprehensive map of rejuvenation genome (October 2024) - 100+ genes
- Demonstrated genome-wide CRISPR activation screens identify causal rejuvenation genes
- Established developmental genes repair multiple aging hallmarks when briefly re-expressed
- Processed 3M cells, 20TB single-cell RNA-seq data using AI/ML
- Developed integrated platform: geneAge + imAge + clinAge

### Challenges

- Understanding system-level rejuvenation program complexity
- Processing massive single-cell datasets (3M cells, 20TB) requires advanced AI/ML
- Translating identified genes into therapeutic interventions

### Impact on Field

Rejuvenation Gene Atlas (October 2024) provides first systematic map of causal genes that reverse aging, moving beyond correlative markers. Identified 100+ validated gene targets enable drug or gene therapy development. CRISPR activation + AI analysis approach demonstrates scalable method for discovering rejuvenation mechanisms. Finding that developmental genes repair multiple aging hallmarks suggests new therapeutic strategy - brief re-expression of developmental programs may reverse aging across multiple cellular systems.

## Organizations

### clock.bio
**Legal Name**: clock.bio Ltd.
**Role in Project**: primary
**Role Description**: Primary organization - developer of Rejuvenation Gene Atlas and integrated platform
**Contribution**: Developed genome-wide CRISPR activation screens in iPSCs, processed 3M cells with AI/ML analysis to identify 100+ rejuvenation genes. Built integrated platform (geneAge + imAge + clinAge). Raised $9.3M in funding.
**Organization Type**: company
**Status**: operational
**Founded**: 2023
**Website**: https://clock.bio/
**Description**: Rejuvenation biology company developing therapies that extend human healthspan by decoding the rejuvenation genome and validating interventions that reverse cellular aging
**Focus**: Rejuvenation biology company developing therapies that extend human healthspan by decoding the rejuvenation genome and validating interventions that reverse cellular aging

### Milner Therapeutics Institute, University of Cambridge
**Role in Project**: institution
**Role Description**: Partner institution providing research facilities and collaboration opportunities
**Contribution**: clock.bio is based at Milner Therapeutics Institute, providing access to cutting-edge research facilities, collaboration opportunities, and proximity to world-class academic research in regenerative medicine and stem cell biology
**Organization Type**: research_center
**Status**: operational
**Website**: https://www.cam.ac.uk/
**Description**: Research institute at University of Cambridge providing cutting-edge research facilities and collaboration opportunities in regenerative medicine and stem cell biology
**Focus**: Biotech research support, Therapeutics translation, Bio-incubator programs

## Locations

### clock.bio Headquarters - Cambridge
**Type**: headquarters
**Address**: The Clifford Allbutt Building, Puddicombe Way, Cambridge, CB2 0AW, United Kingdom
**City**: Cambridge
**State/Region**: Cambridgeshire
**Country**: United Kingdom
**Organizations**: clock.bio

## Products

### Skin Rejuvenation Topicals
**Type**: therapy
**Status**: Preclinical Development
**Development Stage**: Research / Preclinical
**Role in Project**: secondary
**Relationship Description**: Topical treatments for skin aging reversal based on Atlas findings
**Description**: Topical applications aimed at reversing skin aging by targeting pathways identified in the Rejuvenation Gene Atlas.
**Mechanism of Action**: Topical treatments targeting key genes and pathways identified in the geneAge Atlas to reverse skin aging
**Target**: Genes and pathways identified in Rejuvenation Gene Atlas
**Pathway**: Skin aging pathways
**Indications**: [
  {
    "primary": "Skin aging reversal"
  }
]
**Technical Details**:
```yaml
goal: Measurable reversal of biological age in skin
advantage: Rapid data generation and demonstration of biological age reversibility
application: Topical
target_source: Rejuvenation Gene Atlas
```

### Nutraceuticals
**Type**: therapy
**Status**: Preclinical Development
**Development Stage**: Research / Preclinical
**Role in Project**: secondary
**Relationship Description**: Dietary supplements for healthspan extension based on Atlas findings
**Description**: Dietary supplements designed to extend healthspan by modulating aging pathways identified through clock.bio's research.
**Mechanism of Action**: Nutraceuticals designed to modulate aging-related genetic pathways identified in the Rejuvenation Gene Atlas
**Target**: Aging pathways identified in geneAge Atlas
**Pathway**: Systemic aging pathways
**Indications**: [
  {
    "primary": "Healthspan extension"
  }
]
**Technical Details**:
```yaml
advantage: Rapid market entry and data collection on biological age impact
application: Dietary supplement
target_source: Rejuvenation Gene Atlas
```

### Systemic Therapies
**Type**: therapy
**Status**: Discovery
**Development Stage**: Research / Preclinical
**Role in Project**: secondary
**Relationship Description**: Future systemic therapies for comprehensive healthspan extension
**Description**: Future systemic treatments targeting multiple organ systems to reverse aging and extend overall healthspan.
**Mechanism of Action**: Systemic therapies targeting multiple organ systems to reverse aging processes at the cellular level
**Target**: Multiple organ systems
**Pathway**: Systemic aging pathways
**Indications**: [
  {
    "primary": "Systemic healthspan extension"
  }
]
**Technical Details**:
```yaml
goal: Long-term systemic healthspan extension by reversing aging processes
application: Systemic therapy
target_source: Rejuvenation Gene Atlas
```

### clinAge Platform
**Type**: platform
**Status**: In Development
**Development Stage**: Research / Preclinical
**Role in Project**: secondary
**Relationship Description**: Adaptive clinical trial platform for rapid validation of rejuvenation interventions
**Description**: A next-generation clinical trial engine designed for adaptive and rapid validation of rejuvenation interventions in humans, starting with skin topicals and nutraceuticals, and scaling to systemic therapies.
**Mechanism of Action**: Adaptive clinical trial platform designed for rapid validation of rejuvenation therapies in human subjects
**Target**: Human validation of rejuvenation interventions
**Pathway**: Various, depending on specific interventions tested
**Capabilities**:
- Adaptive clinical trial design
- Rapid validation of interventions
- Biological age measurement in humans
- Scalable from topicals to systemic therapies
**Indications**: [
  {
    "primary": "Validation of skin rejuvenation topicals",
    "secondary": [
      "Nutraceuticals",
      "Systemic therapies for healthspan extension"
    ]
  }
]
**Technical Details**:
```yaml
design: Adaptive clinical trial platform
advantage: Rapid, adaptive validation enabling faster iteration
future_scale: Systemic therapies
starting_focus:
  - Skin rejuvenation topicals
  - Nutraceuticals
```

### imAge
**Type**: ai_model
**Status**: Operational
**Development Stage**: Operational
**Role in Project**: secondary
**Relationship Description**: AI system for rapid biological age measurement enabling high-throughput screening
**Description**: AI system that measures biological age from single-cell microscope images, enabling rapid high-throughput screening of rejuvenation interventions without requiring molecular analysis.
**Mechanism of Action**: Deep learning model analyzes cellular morphology features in microscope images to predict biological age. Convolutional neural network extracts features (cell size, shape, nuclear morphology, organelle appearance) that correlate with biological age.
**Target**: Biological age markers visible in cellular morphology
**Pathway**: Cellular morphology changes that correlate with aging
**Capabilities**:
- Single-cell biological age measurement from microscope images
- High-throughput screening capability
- Rapid assessment without molecular analysis
- Zero-shot age prediction
- Cost-effective compared to molecular assays
**Indications**: [
  {
    "primary": "Rapid assessment of cellular biological age",
    "secondary": [
      "High-throughput screening of rejuvenation interventions",
      "Validation of gene activation effects",
      "Compound screening"
    ]
  }
]
**Technical Details**:
```yaml
advantage: Faster and cheaper than molecular aging assays
validation: Validated against epigenetic clocks and other aging biomarkers
architecture:
  type: Convolutional Neural Network or Vision Transformer
  input: Single microscope image (brightfield, phase contrast, or fluorescence)
  output: Biological age score
training_data: Images of cells with known biological ages measured by molecular markers
features_detected:
  - Nuclear size and shape
  - Chromatin organization
  - Organelle appearance
  - Cell size
  - Membrane integrity
```

### Rejuvenation Gene Atlas
**Alternative Names**: geneAge Atlas of Aging and Rejuvenation Genes, Atlas of Rejuvenation
**Type**: platform
**Status**: Research and Development
**Development Stage**: Research / Preclinical
**Role in Project**: primary
**Relationship Description**: Core platform - first comprehensive map of rejuvenation genome identifying 100+ causal genes
**Description**: The world's first comprehensive map of genes that constitute the 'rejuvenation genome'. Developed through genome-wide CRISPR activation screens in human induced pluripotent stem cells (iPSCs), the Atlas identifies over 100 key genetic targets responsible for cellular rejuvenation.
**Mechanism of Action**: Systematic approach to identify genes that reverse cellular aging by testing genome-wide gene activations in artificially aged stem cells. Uses CRISPR activation (dCas9-VPR/SAM system) to upregulate genes, single-cell RNA-seq to measure responses, and AI/ML to identify rejuvenation patterns.
**Target**: Genome-wide gene targets
**Pathway**: Rejuvenation pathways, developmental gene programs, cellular aging reversal mechanisms
**Capabilities**:
- Genome-wide CRISPR activation screening (~20,000 genes)
- Single-cell RNA-seq analysis (3 million cells, 20TB data)
- AI-driven gene ranking and pattern recognition
- Identification of 100+ rejuvenation genes
- Multi-hallmark aging reversal validation
- Zero-shot rejuvenation gene discovery
**Indications**: [
  {
    "primary": "Age-related cellular decline",
    "secondary": [
      "Potential targets for age-related diseases",
      "Therapeutic gene targets for rejuvenation"
    ]
  }
]
**Technical Details**:
```yaml
results:
  limitations:
  safety: Not all genes can be safely activated
  delivery: Technical challenges for in vivo delivery
  in_vitro: Results obtained in cell culture
  tissue_specificity: Validation needed in different cell types
  success_rate: Top hits validate in independent experiments
  gene_categories:
  - Developmental genes
  - Transcription factors
  - Metabolic regulators
  - DNA repair genes
  genes_identified: 100+ validated genes (possibly 151 key targets)
  hallmarks_reversed:
  - DNA damage (γH2AX, 53BP1)
  - Epigenetic age (DNA methylation clock)
  - Telomere length
  - Senescence markers (p16, p21)
  - Mitochondrial function
  - Gene expression patterns
  practical_application:
  drug_targetable: Some genes can be targeted with small molecules
  gene_therapy_targets: Others require viral vectors or mRNA delivery
  combination_therapies: Multiple genes may work synergistically
ai_methods:
  libraries:
  - Scanpy/Seurat (single-cell analysis)
  - MAGeCK (CRISPR screens)
  - PyTorch/TensorFlow (deep learning)
  - scikit-learn (traditional ML)
  algorithms:
  - Deep Neural Networks
  - Random Forest
  - Clustering (UMAP, t-SNE)
  - Dimensionality reduction (PCA, autoencoders)
  - MAGeCK for CRISPR screen analysis
  data_scale:
  cells: 3 million
  total_data: 20TB
  genes_per_cell: ~20,000
  computational_requirements:
  storage: 20TB
  processing: HPC or cloud (AWS/GCP/Azure)
  gpu_training: Required for deep learning models
dataset_size: 3M cells, 20TB
completion_date: October 2024
validation_status: Top candidates validated through targeted experiments
experimental_protocol:
  step_1:
  action: iPSC derivation and expansion
  details: Human iPSCs derived from adult cells using reprogramming factors, expanded under standard conditions (37°C, 5% CO2)
  step_2:
  action: Artificial aging of iPSCs
  method: Prolonged passaging, stress induction, or culture conditions promoting aging
  markers: DNA damage, telomere shortening, altered epigenetics, mitochondrial dysfunction
  step_3:
  action: CRISPR activation library delivery
  system: dCas9-VPR or SAM activation system
  delivery: Lentiviral transduction
  library_size: ~20,000 genes
  step_4:
  action: Cell culture and selection
  duration: 3-7 days for gene activation effects
  step_5:
  cells: 3 million cells total
  action: Single-cell harvest
  step_6:
  action: Single-cell RNA-seq
  platform: 10x Genomics or similar
  data_volume: 20TB raw data
  step_7:
  action: AI analysis
  methods:
  - Deep neural networks
  - Random forest feature importance
  - UMAP/t-SNE clustering
  - MAGeCK hit calling
  step_8:
  action: Validation
  method: Individual gene CRISPR activation in aged iPSCs
  metrics: Biological age, aging markers, gene expression, cellular function
```

## Key People

### Michael Boehler
**Title**: Dr.
**Participation Type**: leadership
**Role in Project**: Chief Business Officer
**Participation Period**: 2025-08-present
**Involvement Period**: {"end":null,"start":"2025-08","status":"active"}
**Expertise**: Life sciences commercialization, pharmaceutical business development, global market strategy
**Biography**: Former BioNTech executive with over 20 years of global experience in life sciences industry. Previously held senior leadership positions at BioNTech, Takeda, Kite Pharma, and Amgen. Played key role in global commercial deployment of mRNA vaccines at BioNTech

### Rodrigo Santos
**Participation Type**: leadership
**Role in Project**: Chief Technology Officer
**Participation Period**: 2023-present
**Involvement Period**: {"end":null,"start":"2023-08","status":"active"}
**Expertise**: Technology development, software engineering, biotechnology platforms
**Biography**: Technology development and implementation expertise

### Markus Gstöttner
**Participation Type**: leadership
**Role in Project**: Chief Executive Officer
**Participation Period**: 2023-present
**Involvement Period**: {"end":null,"start":"2023-08","status":"active"}
**Expertise**: Business strategy, entrepreneurship, biotechnology commercialization
**Biography**: Co-founder of Meatable (cultured meat company), Entrepreneur-in-Residence at BlueYard Capital, experience in public service, management consulting at McKinsey, and development economics

### Koby Baranes
**Participation Type**: founder
**Role in Project**: Co-founder and Head of Science
**Participation Period**: 2023-present
**Involvement Period**: {"end":null,"start":"2023-08","status":"active"}
**Expertise**: Rejuvenation biology, cellular aging, CRISPR screening
**Biography**: Scientist specializing in rejuvenation biology and cellular aging research

### Mark Kotter
**Participation Type**: founder
**Role in Project**: Founder and Executive Chairman
**Participation Period**: 2023-present
**Involvement Period**: {"end":null,"start":"2023-08","status":"active"}
**Expertise**: Stem cell biology, regenerative medicine, synthetic biology, cell therapy
**Biography**: Neurosurgeon and stem cell biologist. Founder and CEO of bit.bio, a synthetic biology and cell therapy company. Professor at University of Cambridge, focusing on regenerative medicine and stem cell biology.

## Links

### [clock.bio Appoints Former BioNTech Executive Dr. Michael Boehler as Chief Business Officer](https://diotimes.com/en/clock-bio-appoints-former-biontech-executive-dr-michael-boehler-as-chief-business-officer/)
**Type**: article
**Relevance**: secondary
**Category**: source
**Publication Date**: 2025-08-27
**Description**: News coverage of Dr. Michael Boehler's appointment as CBO

### [clock.bio Raises $5.3M Seed Funding and Decodes Genetic Atlas of Human Rejuvenation Factors](https://www.biospace.com/press-releases/clock-bio-raises-5-3m-seed-funding-and-decodes-genetic-atlas-of-human-rejuvenation-factors)
**Type**: press_release
**Relevance**: secondary
**Category**: source
**Publication Date**: 2024-10-09
**Description**: BioSpace coverage of clock.bio's seed funding and Atlas completion

### [Our CEO speaks at BioAge's podcast about technology, progress and vision at clock.bio](https://clock.bio/news/)
**Type**: video
**Relevance**: secondary
**Category**: publication
**Publication Date**: 2024-12-01
**Description**: CEO Markus Gstöttner discusses technology, progress and vision at clock.bio on BioAge podcast

### [clock.bio raises 5.3M for rejuvenation roadmap](https://clock.bio/clock-bio-raises-5-3m-for-rejuvenation-roadmap/)
**Type**: article
**Relevance**: secondary
**Category**: publication
**Publication Date**: 2024-10-01
**Description**: Article featured in Business Weekly discussing clock.bio's funding for rejuvenation roadmap

### [clock.bio to slow ageing with 5.3M funding for Atlas of rejuvenation](https://clock.bio/clock-bio-to-slow-ageing-with-5-3m-funding-for-atlas-of-rejuvenation/)
**Type**: article
**Relevance**: secondary
**Category**: publication
**Publication Date**: 2024-10-01
**Description**: Article featured in Cambridge Independent discussing clock.bio's funding and Atlas of rejuvenation

### [clock.bio decodes Atlas of Rejuvenation](https://clock.bio/clock-bio-decodes-atlas-of-rejuvenation/)
**Type**: article
**Relevance**: secondary
**Category**: publication
**Publication Date**: 2024-10-01
**Description**: Article featured in Longevity Technology discussing clock.bio's decoding of the Atlas of Rejuvenation

### [clock.bio's Atlas of Rejuvenation](https://clock.bio/clock-bios-atlas-of-rejuvenation/)
**Type**: article
**Relevance**: secondary
**Category**: publication
**Publication Date**: 2024-10-01
**Description**: Article featured in Endpoint discussing clock.bio's Atlas of Rejuvenation

### [clock.bio Appoints Former BioNTech Executive Dr. Michael Boehler as Chief Business Officer](https://www.prnewswire.com/news-releases/clockbio-appoints-former-biontech-executive-dr-michael-boehler-as-chief-business-officer-302539598.html)
**Type**: press_release
**Relevance**: secondary
**Category**: publication
**Publication Date**: 2025-08-27
**Description**: Press release announcing Dr. Michael Boehler's appointment as CBO

### [clock.bio Raises $5.3M Seed Funding and Decodes Genetic Atlas of Human Rejuvenation Factors](https://www.businesswire.com/news/home/20241009483345/en/clock.bio-Raises-%245.3M-Seed-Funding-and-Decodes-Genetic-Atlas-of-Human-Rejuvenation-Factors)
**Type**: press_release
**Relevance**: primary
**Category**: publication
**Publication Date**: 2024-10-09
**Description**: Press release announcing $5.3M seed funding and completion of Rejuvenation Gene Atlas

### [clock.bio Launches to Decode Rejuvenation Biology Across the Human Genome](https://www.businesswire.com/news/home/20230831929429/en/clock.bio-Launches-to-Decode-Rejuvenation-Biology-Across-the-Human-Genome)
**Type**: press_release
**Relevance**: primary
**Category**: publication
**Publication Date**: 2023-08-31
**Description**: Press release announcing clock.bio's launch with $4M seed funding

## Financials

### funding
**Amount**: $5.3 million USD
**Amount (Numeric)**: 5300000
**Funding Date**: 2024-10-09
**Source**: LocalGlobe
**Funding Type**: Seed
**Description**: Seed funding to advance Rejuvenation Gene Atlas development and decode genetic atlas of human rejuvenation factors
**Details**:
```yaml
year: 2024
month: October
stage: Seed
investors:
  - LocalGlobe
  - BlueYard Capital
  - Onsight Ventures
  - Dr. Jonathan Milner
lead_investor: LocalGlobe
```

### funding
**Amount**: $4 million USD
**Amount (Numeric)**: 4000000
**Funding Date**: 2023-08-31
**Source**: LocalGlobe
**Funding Type**: Seed
**Description**: Initial seed funding to launch company and begin decoding rejuvenation biology across the human genome
**Details**:
```yaml
year: 2023
month: August
stage: Seed
investors:
  - LocalGlobe
  - BlueYard Capital
  - Onsight Ventures
  - Dr. Jonathan Milner
lead_investor: LocalGlobe
```

## Events

### Company Launch
**Date**: 2023-08-31
**Type**: launch
**Description**: clock.bio launched out of stealth mode with $4M in seed funding, announcing mission to decode rejuvenation biology across the human genome
**Details**:
```yaml
investors:
  - LocalGlobe
  - BlueYard Capital
  - Onsight Ventures
  - Dr. Jonathan Milner
funding_amount: $4 million
```

### Funding and Milestone
**Date**: 2024-10-09
**Type**: funding
**Description**: Raised $5.3M in seed funding and announced completion of Rejuvenation Gene Atlas, decoding genetic atlas of human rejuvenation factors. Identified 100+ genes responsible for cellular rejuvenation
**Details**:
```yaml
investors:
  - LocalGlobe
  - BlueYard Capital
  - Onsight Ventures
  - Dr. Jonathan Milner
milestone: Completion of Rejuvenation Gene Atlas
funding_amount: $5.3 million
genes_identified: 100+
```

### Executive Appointment
**Date**: 2025-08-27
**Type**: executive_appointment
**Description**: Appointed Dr. Michael Boehler, former BioNTech executive, as Chief Business Officer to accelerate the company's rejuvenation biology platform and commercialization efforts
**Details**:
```yaml
role: Chief Business Officer
executive: Dr. Michael Boehler
experience: Over 20 years in life sciences, key role in mRNA vaccine deployment
previous_role: BioNTech executive
```

## Partnerships

### research
**Date**: 2023-08-01
**Focus**: Research collaboration and access to cutting-edge research facilities in regenerative medicine and stem cell biology
**Description**: clock.bio is based at the Milner Therapeutics Institute at the University of Cambridge, providing access to cutting-edge research facilities, collaboration opportunities, and proximity to world-class academic research in regenerative medicine and stem cell biology
**Partner Organizations**:
- Milner Therapeutics Institute, University of Cambridge (partner)
  - Provides research facilities, collaboration opportunities, and academic environment
- clock.bio (partner)
  - Company based at the institute, utilizing research facilities and collaboration opportunities
**Details**:
```yaml
partner: Milner Therapeutics Institute, University of Cambridge
benefits:
  - Access to cutting-edge research facilities
  - Collaboration opportunities
  - Proximity to world-class academic research
  - Focus on regenerative medicine and stem cell biology
location: The Clifford Allbutt Building, Puddicombe Way, Cambridge, CB2 0AW, United Kingdom
collaboration_type: Research Collaboration and Location
```
